IDEAYA Biosciences, Inc. reports that GlaxoSmithKline has terminated their collaboration agreement effective March 9, 2026. The company will receive two clinical programs, IDE275 and IDE705, during a 90-day transition period and maintains a cash runway expectation into 2030.